Endocrinology

Your daily dose of the clinical news you may have missed.

Amgen's investigational maridebart cafraglutide in a phase 1 trial led to durable weight reduction following less frequent and lower doses, the company said.

Among women with PCOS, the risk for a suicide attempt was highest (by a factor of 9) among young adults aged 20 to 40 years, followed by adolescents.

Mean placebo-adjusted SBP change from baseline at 36 weeks was 8.6 mm Hg in adults with obesity, according to authors of the SURMOUNT-1 ABPM substudy.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Adolescents with overweight or obesity and baseline HbA1c 6.3%-6.4% were at 72-fold greater risk for T2D than those with HbA1c of 5.5%, a new cohort study finds.

The Boxed Warning reflects FDA research into severe adverse events including hospitalization and death in persons with CKD treated with denosumab.

Remission of T2D, regardless of duration of remission, was associated with reduced risk of diabetes-related CKD and CVD in a post hoc analysis of Look AHEAD.

The digital prescription therapeutic when used along with prescription diabetes therapies, can help reduce the costs of managing the disease and enhance standard of care.

The GLP-1 RAs Wegovy, Ozempic, Mounjaro, and Zepbound have taken up more real estate on the US map in some areas than others. Click to find out more.

Your daily dose of the clinical news you may have missed.

Findings from new study suggest that promoting healthy coping strategies for stress during early life can reduce cardiometabolic risk, report researchers.

Your daily dose of the clinical news you may have missed.

While the FDA's preliminary evaluation has not surfaced evidence of a link, the agency says it "cannot definitively rule out that a small risk may exist," and so will continue research.

Semaglutide was associated with a lower risk of first-time and recurrent suicidal ideations in patients with obesity or overweight or T2D, according to new study.

The novel nonhormonal compound significantly reduced vasomotor symptoms and sleep disturbance while improving quality of life, according to findings.

Individuals with "lean NAFLD" may be at similar risk of NASH, cirrhosis, nonliver cancer, and death as as those with NAFLD and overweight or obesity, authors say.

In an open letter to the public, Lilly decries use of tirzepatide products Mounjaro and Zepbound for nonmedical purposes and warns of counterfeit formulations.

Your daily dose of the clinical news you may have missed.

The American Board of Obesity Medicine says annual first-time certificates now exceed those for cardiology, pulmonology, and medical oncology.

Study participants randomized to placebo for 1 year after 36 weeks on tirzepatide had mean weight regain of 14% vs augmented loss among those who continued on the medication.

While incretin-based antiobesity medications are the optimal treatment for some, there are other less costly approaches that can support weight loss success, this author says.

The dual GIP/GLP-1 mimetic is available by prescription for adults with obesity or overweight with comorbidities and Lilly is offering a savings card program.

Crinecerfont was granted FDA breakthrough therapy designation for the treatment of congenital adrenal hyperplasia.